Merck to Divest CDMO Business Across Five US Sites to Lonza
European Pharmaceutical Review reports that Merck is divesting its CDMO (Contract Development and Manufacturing Organization) business across five US sites to Lonza.
This move is significant in the pharmaceutical industry, potentially reshaping the landscape of contract manufacturing. The article does not provide specific details about the terms of the deal or the timeline for the transition. However, this reorganization underscores Merck's strategic shift and could signal a game-changer in the sector.
As previously mentioned, the industry is experiencing a surge in demand for contract manufacturing services, driven by the complex and costly development of new drugs. This trend has led to a symphony of partnerships and acquisitions, with companies like Lonza positioning themselves to meet this growing need.
In light of the above, Merck's decision to sell its CDMO business could be seen as a metamorphosis in its strategic direction, allowing the company to focus on its core pharmaceutical research and development activities.